TY - JOUR
T1 - mAb Das-1 recognizes 3’-Sulfated Lewis A/C, which is aberrantly expressed during metaplastic and oncogenic transformation of several gastrointestinal Epithelia
AU - Brown, Jeffrey W.
AU - Das, Koushik K.
AU - Kalas, Vasilios
AU - Das, Kiron M.
AU - Mills, Jason C.
N1 - Funding Information:
This study received support from the following sources: JWB is supported by the Department of Defense, through the PRCRP program under Award No. W81XWH-20-1-0630, NIH T32 DK007130-42, the Digestive Disease Research Core Centers Pilot and Feasibility Grant as part of P30 DK052574, the American Gastroenterological Association AGA2021-5101, the National Institute of Diabetes and Digestive and Kidney Diseases R21 AI156236, and the Doris Duke Charitable Foundation, Fund to Retain Clinical Scientists. JCM is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK111369, R01 DK094989, R01 DK105129, R01 DK110406, P30 DK056338), the Alvin J. Siteman Cancer Center-Barnes Jewish Foundation Cancer Frontier Fund, The National Institutes of Health National Cancer Institute (P30 CA09182, R01 CA239645, R01 CA246208), and the BETRNet (U54 CA163060). The National Center for Functional Glycomics Glycan Array resource and much appreciated assistance with the analysis was supported by R24 GM098791, R24 GM137763, and P41 GM103694. VK was supported by the Medical Scientist Training Program Training grant T32 GM07200. Development of mAb Das-1 was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases research grants R01 DK47673 and R01 DK63618, awarded to KMD. We thank Jamie Heimburg-Molinaro and Richard D. Cummings for both performing and analyzing the glycan array data. We thank Kian-Huat Lim for providing us with slides of KPC mouse.
Publisher Copyright:
© 2021 Brown et al.
PY - 2021/12
Y1 - 2021/12
N2 - Introduction Multiple previous studies have shown the monoclonal antibody Das-1 (formerly called 7E12H12) is specifically reactive towards metaplastic and carcinomatous lesions in multiple organs of the gastrointestinal system (e.g. Barrett’s esophagus, intestinal-type metaplasia of the stomach, gastric adenocarcinoma, high-grade pancreatic intraepithelial neoplasm, and pancreatic ductal adenocarcinoma) as well as in other organs (bladder and lung carcinomas). Beyond being a useful biomarker in tissue, mAb Das-1 has recently proven to be more accurate than current paradigms for identifying cysts harboring advanced neoplasia. Though this antibody has been used extensively for clinical, basic science, and translational applications for decades, its epitope has remained elusive. Methods In this study, we chemically deglycosylated a standard source of antigen, which resulted in near complete loss of the signal as measured by western blot analysis. The epitope recognized by mAb Das-1 was determined by affinity to a comprehensive glycan array and validated by inhibition of a direct ELISA. Results The epitope recognized by mAb Das-1 is 3’-Sulfo-Lewis A/C (3’-Sulfo-LeA/C). 3’-Sulfo-LeA/C is broadly reexpressed across numerous GI epithelia and elsewhere during metaplastic and carcinomatous transformation. Discussion 3’-Sulfo-LeA/C is a clinically important antigen that can be detected both intracellularly in tissue using immunohistochemistry and extracellularly in cyst fluid and serum by ELISA. The results open new avenues for tumorigenic risk stratification of various gastrointestinal lesions.
AB - Introduction Multiple previous studies have shown the monoclonal antibody Das-1 (formerly called 7E12H12) is specifically reactive towards metaplastic and carcinomatous lesions in multiple organs of the gastrointestinal system (e.g. Barrett’s esophagus, intestinal-type metaplasia of the stomach, gastric adenocarcinoma, high-grade pancreatic intraepithelial neoplasm, and pancreatic ductal adenocarcinoma) as well as in other organs (bladder and lung carcinomas). Beyond being a useful biomarker in tissue, mAb Das-1 has recently proven to be more accurate than current paradigms for identifying cysts harboring advanced neoplasia. Though this antibody has been used extensively for clinical, basic science, and translational applications for decades, its epitope has remained elusive. Methods In this study, we chemically deglycosylated a standard source of antigen, which resulted in near complete loss of the signal as measured by western blot analysis. The epitope recognized by mAb Das-1 was determined by affinity to a comprehensive glycan array and validated by inhibition of a direct ELISA. Results The epitope recognized by mAb Das-1 is 3’-Sulfo-Lewis A/C (3’-Sulfo-LeA/C). 3’-Sulfo-LeA/C is broadly reexpressed across numerous GI epithelia and elsewhere during metaplastic and carcinomatous transformation. Discussion 3’-Sulfo-LeA/C is a clinically important antigen that can be detected both intracellularly in tissue using immunohistochemistry and extracellularly in cyst fluid and serum by ELISA. The results open new avenues for tumorigenic risk stratification of various gastrointestinal lesions.
UR - http://www.scopus.com/inward/record.url?scp=85122234243&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0261082
DO - 10.1371/journal.pone.0261082
M3 - Article
C2 - 34910746
AN - SCOPUS:85122234243
VL - 16
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 12
M1 - e0261082
ER -